Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1

Mechanisms of Alternative Pre-Messenger RNA Splicing

Black, D. L. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161720 · Cited by 2,704

Listening to silence and understanding nonsense: exonic mutations that affect splicing

Cartegni, L., Chew, S. L., & Krainer, A. R. (2002) · Nature Reviews Genetics · doi:10.1038/nrg775 · Cited by 2,209

Mechanisms and Regulation of Alternative Pre-mRNA Splicing

Lee, Y., & Rio, D. C. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034316 · Cited by 1,291

Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches

Chen, M., & Manley, J. L. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2777 · Cited by 1,284

Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?

Burghes, A. H. M., & Beattie, C. E. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2670 · Cited by 723

Splicing mutations in human genetic disorders: Examples, detection, and confirmation

Anna, A., & Monika, G. (2018) · Journal of Applied Genetics · doi:10.1007/s13353-018-0444-7 · Cited by 657

Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy

Brichta, L. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg256 · Cited by 382

Antisense Oligonucleotide Therapies for Neurodegenerative Diseases

Bennett, C. F., Krainer, A. R., & Cleveland, D. W. (2019) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070918-050501 · Cited by 353

Systemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy

Valori, C. F., Ning, K., Wyles, M., Mead, R. J., Grierson, A. J., Shaw, P. J., & Azzouz, M. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000830 · Cited by 285

Spinal muscular atrophy: mechanisms and therapeutic strategies

Lorson, C. L., Rindt, H., & Shababi, M. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq147 · Cited by 209

In silico tools for splicing defect prediction: a survey from the viewpoint of end users

Jian, X., Boerwinkle, E., & Liu, X. (2014) · Genetics in Medicine · doi:10.1038/gim.2013.176 · Cited by 146

SCNM1, a Putative RNA Splicing Factor That Modifies Disease Severity in Mice

Buchner, D. A., Trudeau, M., & Meisler, M. H. (2003) · Science · doi:10.1126/science.1086187 · Cited by 137

Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies

Alexaki, A., Hettiarachchi, G. K., Athey, J. C., Katneni, U. K., Simhadri, V., Hamasaki-Katagiri, N., Nanavaty, P., Lin, B., Takeda, K., Freedberg, D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51984-2 · Cited by 78

Spliceosome protein (SRp) regulation of glucocorticoid receptor isoforms and glucocorticoid response in human trabecular meshwork cells

Jain, A., Wordinger, R. J., Yorio, T., & Clark, A. F. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-8497 · Cited by 46

HnRNP L and hnRNP LL antagonistically modulate PTB-mediated splicing suppression of CHRNA1 pre-mRNA

Rahman, M. A., Masuda, A., Ohe, K., Ito, M., Hutchinson, D. O., Mayeda, A., Engel, A. G., & Ohno, K. (2013) · Scientific Reports · doi:10.1038/srep02931 · Cited by 44

Unveiling the potential of antisense oligonucleotides: Mechanisms, therapies, and safety insights

Ersöz, E., & Demir‐Dora, D. (2024) · Drug Development Research · doi:10.1002/ddr.22187 · Cited by 34